Ultromics Receives Investment to Enhance Heart Failure Detection in Women

Ultromics Enhances Heart Health Detection with New Investment

Ultromics, a leader in developing AI-driven cardiology solutions, announced today a significant investment from the American Heart Association's Go Red for Women Venture Fund. This funding represents a critical step toward addressing a major health challenge: the early identification of heart failure with preserved ejection fraction (HFpEF), a condition that predominantly affects women but frequently remains undiagnosed.

Heart failure is a leading cause of mortality among women; however, its early symptoms often go unrecognized or are mislabeled as mere signs of aging or other conditions. Alarmingly, studies indicate that women are twice as likely as men to suffer from HFpEF, and up to 64% of cases evade diagnosis in clinical settings. The overlooked nature of this condition has led to delays in access to essential, life-saving therapies that can mitigate hospital stays and enhance survival rates.

Tracy Warren, Senior Managing Director at the Go Red for Women Venture Fund, commented on the importance of this strategic investment: “Addressing the diagnostic gap and identifying conditions before irreversible damage occurs is essential for improving women's health and that of all patients.” The fund's support highlights a shared mission to promote innovation in medical technology that improves patient outcomes, particularly for women.

Ultromics’ flagship AI platform, EchoGo® Heart Failure, aims to transform routine heart ultrasounds into powerful diagnostic tools. Built upon one of the world's largest and diverse echocardiography datasets, the AI technology has been validated with real patient outcomes, moving beyond subjective interpretations to provide quantifiable insights into heart function.

“This technology is a game-changer,” said Ross Upton, PhD, the CEO and Founder of Ultromics. “For far too long, clinicians were limited in their ability to effectively identify HFpEF using standard diagnostic tools. Our EchoGo solution enhances their ability to detect disease at its earliest stages, leading to better treatment outcomes.”

The AI system's precision is demonstrated in the fact that it has analyzed over 430,000 echocardiograms across hospitals in the U.S. and U.K., validating a remarkable 93% of patients for HFpEF diagnoses as compared to a mere 40% success rate with traditional risk scores in similar populations. This impressive performance underlines Ultromics' commitment to addressing significant disparities in cardiac care for women.

With strong backing from the Go Red for Women initiative and partnerships with esteemed healthcare institutions like NHS and Mayo Clinic, Ultromics is on a mission to revolutionize the ways heart disease is diagnosed and treated. As heart disease continues to be a formidable challenge for women, investment in AI-driven solutions that ensure equitable access to care becomes all the more critical.

As Ultromics moves ahead with these advancements, its mission echoes a vital sentiment—closing the health equity gap and ensuring better outcomes for women affected by heart disease. This investment speaks volumes about the growing recognition of how technology can significantly improve health outcomes and ultimately save lives.

For additional information about Ultromics and its innovative solutions, please visit their website at www.ultromics.com.